Cue Biopharma is trading 6.25% down at $28.52 after no verified company-specific announcement was identified for August 13, 2026.
- The latest official release found was dated August 3 and covered James M. Ahlers’ CFO appointment and the CUE-221 investigational new drug submission.
- The decline is occurring despite a broadly firmer market, with the S&P 500, Nasdaq Composite, and Dow Jones all higher.
- The specific catalyst remains unconfirmed.